drugset / Trial / NCT06884891
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
RandomizedParallel-groupQuadruple-blindTreatment
Summary
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase Ⅲ comparative study to evaluate the efficacy and safety of QL2108 to Dupixent® in adult subjects with moderate-to-severe atopic dermatitis. A total of 520 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2108 injection or Dupixent®
Timeline
- Start
- 2025-04
- Primary completion
- 2027-05
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | QL2108 | Unknown | 300 mg | Subcutaneous |